Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum92882ArticlesСтатьиResearch ArticleEffektivnost' i bezopasnost' terapii edinym ingalyatorom u bol'nykh bronkhial'noy astmoyЭффективность и безопасность терапии единым ингалятором у больных бронхиальной астмойEmel'yanovA. VЕмельяновА. ВСанкт-Петербургская медицинская академия последипломного образования15032009113VOL 11, NO3 (2009)ТОМ 11, №3 (2009)454928122021Copyright ©; 2009, Consilium MedicumCopyright ©; 2009, ООО "Консилиум Медикум"2009Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/92882

Комбинированная терапия ингаляционными глюкококортикостероидами (ИГКС) и b2-адреномиметиками длительного действия (сальметеролом и формотеролом) играет важную роль при лечении больных бронхиальной астмой (БА), что нашло отражение в международных согласительных документах [17]. Добавление формотерола или сальметерола улучшает контроль за течением БА более эффективно, чем увеличение дозы ИГКС у пациентов с недостаточным эффектом при использовании низких доз этих препаратов [9, 29]. Результаты клинических исследований явились основанием для создания и использования в клинической практике комбинаций сальметерол/флутиказон (серетид), формотерол/будесонид (симбикорт), беклометазон дипропионат/формотерол (фостер), которые являются высокоэффективными средствами для лечения БА. В настоящее время разработан новый режим дозирования cимбикорта, предусматривающий использование его как для поддерживающего лечения (минимально 2 ингаляции в сутки), так и «по потребности» (максимально до 12 ингаляций в сутки) для купирования симптомов и предупреждения развития обострений БА у больных 18 лет и старше. Он получил название терапии единым ингалятором. В 2006 г. такой режим лечения был зарегистрирован в странах Европейского Союза, а затем в 2007 г. и в России.

Цой А.Н., Архипов В.В., Чапурин С.А., Чурилин Ю.Ю. Фармакоэкономическое исследование новой концепции применения Симбикорта у больных бронхиальной астмой. Пульмонология. 2007; 3: 34–40.Adcock I, Maneechotesuwan K, Usmani O. Molecular interaction between glucocorticoids and long - acting b2 agonists. J Allergy Clin Immunol 2002; 110 (6, suppl.): 261s–8s.Adcock I.M. Molecular mechanisms of glucocorticoid actions. Pulm Pharm Ther 2000; 13 (3): 115–26.Anderson G.P., Linden A, Rabe K.F. Why are long - acting beta - adrenoceptor agonists long acting ? Eur Respir J 1994; 7 (3): 569–78.Balanag V.M., Yunus F, Yang P-C, Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in treatment of acute asthma. Pulm Pharm Ther 2006; 19: 139–47.Barnes P.J., Pedersen S, Busse W.W. Efficacy and safety of inhaled corticosteroids. New development. Am J Respir Crit Care Med 1998; 157 (3, pt 2): 1S–53S.Barnes P.J. Scientific rationale for combination inhalers with a long - acting and b2 - agonists and corticosteroids. Eur Respir J 2002; 19 (1): 182–91.Barnes P.J. Scientific rationale for using single inhaler for asthma control. Eur Respir J 2007; 29 (3): 587–95.Bateman E.D., Boushley H.A., Bousquet J et al. Can guideline - defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med 2004; 170: 836–44.Bousquet J, Boulet L-P, Peters M.J. et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs high dose salmeterol/fluticasone. Respir Medicine 2007; 101 (12): 2437–46.Cazzola M, Imperatore F, Salzillo A et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrythmias and hypoxemia. Chest 1998; 114: 411–5.Cazzola M, Matera M.G., Donner C.F. Inhaled beta2 - adrenoreceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005; 65 (12): 1595–610.Erin E.M., Zachrasiewicz A.S., Nicholson G.C. et al. Topical corticosteroid inhibits interleukin 4,5 and 13 in nasal secretions following allergen challenge. Clin Exp Allergy 2005; 35 (12): 1608–14.Ferrari M, Balestreri F, Baratieri S et al. Evidence of the rapid protective effect of formoterol dry - powder inhalation against exercise - induced bronchospasm in athletes with asthma. Respiration 2000; 67 (5): 510–3.Forensi A, Morelli M.C., Catena E. Low dose budesonide with the addition of increased dose during exacerbations is effective in long - term asthma control. Chest 2000; 117 (2): 440–6.Gibson P.J., Saltos N, Fakes K. Acute anti - inflammatory effect of inhaled budesonide in asthma. A randomized controlled trial. Am J Respir Crit Care Med 2001; 163 (1): 32–6.Global Initiative for Аsthma. NHLB/WHO Workshop Report.-National Heart Lung Blood Institute, Publication number 02–3659, revised 2006. Пер. с англ. Под ред. А.Г.Чучалина. М.: Атмосфера, 2007.Guhan A.R., Cooper S, Oborne J et al. Systemic effect of formoterol and salmeterol: a dose - response comparison in healthy subjects. Thorax 2000; 55: 650–6.Ind P.W., Villasante C, Shiner R.Jet al. Safety of formoterol by Turbuhaled as reliver medication compared with terbutaline in moderate asthma. Eur Respir J 2002; 20 (4): 859–66.Johansson G, Andreasson E.B., Larsson P.E., Vogelmeier C.F. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of аsthma. Pharmacoeco - nomics 2006; 24 (7): 695–708.Ketchell R.I., Jensen M.W., Lumley P et al. Rapid effect of inhaled fluticasone propionate on airway hyperresponsiveness to adenosine 5 - monophosphate in mild asthma. J Allegry Clin Immunol 2002; 110 (4): 603–6.Ketchell R.I., Jensen M.W., Spina D et al. Dose - related effects of formoterol on airway hyperresponsiveness to adenosine 51 monophosphate and histamine. Eur Respir J 2002; 19 (4): 611–6.Kuna P, Peters M.J., Manjra A.I. et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007; 61 (5): 725–36.Maneechotesuwan K, Essilfie-Quaye S, Meah S et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 2005; 128 (4): 1936–42.Nightingale J.A., Rogers D.F., Barnes P.J. Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. Am J Respir Crit Care Med 1999; 159 (6): 1786–90.O\'Byrne P, Bisgaard H, Godard P.P. et al. Budesonide/Formoterol combination therapy as both meintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171 (2): 129–36.Palmqvist M, Persson G, Lazer L et al. Inhaled dry - powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10 (11): 2484–9.Partridge M.R., van Molen T, Myrseth S-E, Busse W.W. Attitude and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulmonary Medicine 2006; 6: 13.Pauwells R.A., Lofdahl C-G, Postma D et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337 (20): 1412–8.Pauwels R.A., Sears M.R., Campbell M et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003; 22: 787–94.Price D, Wiren A, Kuna P. Cost - effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy 2007; 62 (10): 1189–98.Rabe K, Pizzichini E, Stallberg B et al. Budesonide/Formoterol in a single inhaler for maintenance and relief in mild - to - moderate asthma. A randomized, double blind trial. Chest 2006; 129 (2): 246–56.Rabe K.F., Atienza T, Magyar P et al. Effect of budesonide in combination with formoterol for reliver therapy in asthma exacerbations: a randomised controlled, double blind study. Lancet 2006; 368: 744–53.Rosenborg J, Bengtsson T, Larsson P et al. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics, Eur J Clin Pharmacol 2000; 56 (5): 363–70.Scicchitano R, Aalbers R, Ukena D et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20 (9): 1403–18.Stahl E, Postma D.S. , Svensson K et al. Formoterol used as needed improves health - related quality of life in asthmatic patients uncontrolled with inhaled corticosteroids. Respir Med 2003; 97 (9): 1061–6.Tatersfield A.E., Lofdahl C.G., Postma D.S. et al. Comparison of formoterol and terbutaline for as - needed treatment of asthma: a randomized trial. Lancet 2001; 357 (9252): 257–61.Tatersfield A.E., Postma D.S., Barnes P et al. Exacerbations of asthma. A descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med 1999; 160 (2): 594–9.Vogelmeier C, D\'Urzo A, Pauwels R et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26 (5): 819–28.Wark P.A.B., Gibson P.G. Asthma exacerbation. 3 Pathogenesis. Thorax 2006; 61 (11): 909–15.